Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best emerging technology stocks to buy right now. The company develops ...

If two’s company and three’s a crowd, then 30-plus is more like 10 crowds—and like a crowded elevator with that many people inside, a drug pipeline top-heavy with top candidates risks not carrying any ...

Kura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified ...

Needham analyst Ami Fadia maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of $151.00. Ami Fadia’s rating is based on a combination of ...

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of ...

Jones Day served as legal advisor to MPE Based in Cleveland and Boston, MPE Partners invests in lower middle market companies with EBITDA between $8 million and $40 million MPE targets high-value ...

HAMBURG, GERMANY / ACCESSWIRE / November 15, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today presents at its Capital Markets Day how the Company is ...

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene ...

Churchill Asset Management and BMO Sponsor Finance provided financing to support the transaction Jones Day served as legal advisor to MPE Based in Cleveland and Boston, MPE Partners invests in lower ...

Wednesday, Precision BioSciences Inc DTIL announced the completion of a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel), Precision's lead ...

CLEVELAND and BOSTON, Aug. 22, 2024 /PRNewswire/ -- MPE Partners ("MPE" or "Morgenthaler Private Equity"), along with its portfolio company Precision Pipeline Services ("Precision"), announced today ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, launched today with more than $100 million in financing since its inception from premier ...